Pharmacy Medical Policy Updates
The following Pharmacy Medical Policy programs will be updated Feb. 1, 2025:
Effective March 1, 2025:
- Biologic Immunomodulators
- Cibinqo
- HCPA Biologics
- Healthcare Administered MS
- IL-4 inhibitors
- IL-5 inhibitors
- IL-13 inhibitors
- Multiple Sclerosis
- Nasal Inhalers
- Niemann-Pick Type C Agents
- Sohonos
- Tezspire
- Tryvio
- Weight Management
- Xolair
- Yorvipath
- Zeposia
Many of our pharmacy medical policies are maintained through our pharmacy benefit manager, Prime Therapeutics.
To find pharmacy medical policies specific to a medication list, please select a medication list at the bottom of our prior authorization page of our website, https://www.bcbsks.com/providers/precertification-prior-authorization.
If you have any questions regarding this newsletter, please contact your BCBSKS provider representative/consultant.